WallStreetZenWallStreetZen

NASDAQ: PTGX
Protagonist Therapeutics Inc Earnings & Revenue

PTGX past revenue growth

How has PTGX's revenue growth performed historically?
Company
125.73%
Industry
169.3%
Market
17.86%
PTGX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PTGX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PTGX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PTGX earnings and revenue history

Current Revenue
$60.0M
Current Earnings
-$79.0M
Current Profit Margin
-131.6%

PTGX Return on Equity

Current Company
-27.5%
Current Industry
-63.4%
Current Market
188%
PTGX's Return on Equity (-27.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PTGX announces earnings.

PTGX Return on Assets

Current Company
-25.3%
Current Industry
3.2%
PTGX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PTGX Return on Capital Employed

Current Company
-23.45%
Current Industry
19.9%
PTGX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PTGX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PTGX$60.00M-$75.64M-$78.96M+14.17%N/A
AUTL$1.70M-$152.71M-$208.38M+2.90%N/A
RCUS$117.00M-$285.00M-$307.00M+69.54%N/A
INBX$1.80M-$206.56M-$241.36M-26.85%N/A
EWTX$0.00-$98.43M-$100.16MN/AN/A

PTGX earnings dates

Next earnings date
May 2, 2024

Protagonist Therapeutics Earnings & Revenue FAQ

What were PTGX's earnings last quarter?

On Invalid Date, Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 2023 earnings per share (EPS) of $0.52, up 174.29% year over year. Total Protagonist Therapeutics earnings for the quarter were $27.34 million. In the same quarter last year, Protagonist Therapeutics's earnings per share (EPS) was -$0.70.

If you're new to stock investing, here's how to buy Protagonist Therapeutics stock.

What was PTGX's earnings growth in the past year?

As of Q1 2024, Protagonist Therapeutics's earnings has grown year over year. Protagonist Therapeutics's earnings in the past year totalled -$78.96 million.

What is PTGX's earnings date?

Protagonist Therapeutics's earnings date is Invalid Date. Add PTGX to your watchlist to be reminded of PTGX's next earnings announcement.

What was PTGX's revenue last quarter?

On Invalid Date, Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 2023 revenue of $60.00 million up Infinity% year over year. In the same quarter last year, Protagonist Therapeutics's revenue was $0.00.

What was PTGX's revenue growth in the past year?

As of Q1 2024, Protagonist Therapeutics's revenue has grown 125.73% year over year. This is 43.57 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Protagonist Therapeutics's revenue in the past year totalled $60.00 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.